May 13th, 2016
Sometimes, big opportunities spring from the smallest seeds—or in the case of a landmark call to action from the White House today—bugs.
The bugs I’m talking about are the trillions of microbes that live in and on us, collectively known as the human microbiome.
Throughout medical history, we saw these microbiota as the enemy—a source of illness to be eradicated. Yet recent discoveries have revealed that the microbiome plays a unique and crucial role in disease and wellness.
Today, microbiome science is exploding, with advances occurring in parallel across many disease areas. At Janssen, we believe the microbiome presents an unprecedented opportunity to change the face and future of healthcare, and we are seeking to use these tiny bugs in big ways to not only treat disease, but also to intercept illness and promote health.
The Microbiome Gets a Funding Boost
We are certainly not alone in our quest.
Today, the White House Office of Science & Technology Policy (OSTP) announced The National Microbiome Initiative to prioritize funding and other resources to realize the promise of microbiome science.
To translate today’s exciting efforts into interventions to improve human health, the life science industry has a unique opportunity to evolve and accelerate novel drug discovery and develop approaches that are potentially more natural and personalized.